Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
88%
Non Small Cell Lung Cancer
56%
Metastatic Melanoma
45%
Solid Malignant Neoplasm
38%
Chemotherapy
33%
Malignant Neoplasm
32%
Biological Marker
29%
Adverse Event
29%
Diseases
27%
Ipilimumab
27%
Nivolumab
26%
Progression Free Survival
25%
Dabrafenib
23%
Pharmacokinetics
21%
Overall Survival
21%
Circulating Tumor DNA
21%
Monotherapy
19%
Carboplatin
18%
Clinical Trial
18%
Neoplasm
18%
Pembrolizumab
15%
Small Cell Lung Cancer
15%
Pharmacodynamics
13%
Trametinib
13%
Recurrent Disease
12%
Cisplatin
11%
Epidermal Growth Factor Receptor
11%
Immune Checkpoint Inhibitor
11%
Mesothelioma
11%
Immunotherapy
10%
Phase II Trials
10%
Pemetrexed
10%
Pleura Mesothelioma
10%
Maximum Tolerated Dose
8%
Recurrence Free Survival
8%
Antitumor Activity
8%
Sodium Fluoride
8%
Programmed Death 1 Receptor
8%
Survival Rate
7%
Advanced Cancer
7%
Nausea
7%
Polyethylene Terephthalate
7%
Mitogen Activated Protein Kinase Kinase Inhibitor
7%
Colorectal Carcinoma
6%
Lung Cancer
6%
Tolerability
6%
Programmed Death 1 Ligand 1
6%
Placebo
6%
Programmed Cell Death
6%
Docetaxel
6%
Medicine and Dentistry
Melanoma
100%
Metastatic Melanoma
49%
Circulating Tumor DNA
36%
Non Small Cell Lung Cancer
34%
Diseases
26%
Tumor
22%
Biological Marker
21%
Circulating Tumor Cell
21%
Ipilimumab
19%
Nivolumab
18%
Metastatic Carcinoma
17%
Neoplasm
15%
Overall Survival
15%
Droplet Digital Polymerase Chain Reaction
14%
Radiation Therapy
13%
Malignant Neoplasm
13%
Progression Free Survival
13%
Targeted Therapy
13%
Recurrent Disease
12%
Pleura Mesothelioma
12%
Arm
11%
Positron Emission Tomography
11%
Treatment Response
10%
Cancer
10%
Clinical Trial
10%
Sodium Fluoride
10%
Small Cell Lung Cancer
10%
Uvea Melanoma
10%
Adverse Event
9%
Mesothelioma
9%
Programmed Death-Ligand 1
9%
Solid Malignant Neoplasm
9%
Pembrolizumab
9%
Epidermal Growth Factor Receptor
8%
Carboplatin
8%
Fluorodeoxyglucose F 18
8%
Dabrafenib
8%
Immune Checkpoint Inhibitor
8%
Cisplatin
8%
Disease Exacerbation
7%
Recurrence Free Survival
7%
Systemic Therapy
6%
MEK Inhibitor
6%
Adjuvant Therapy
6%
Monotherapy
6%
Polyethylene Terephthalate
5%
Cancer Treatment
5%
Programmed Death 1 Receptor
5%
Survival Rate
5%
Melanoma Cell
5%
Biochemistry, Genetics and Molecular Biology
Circulating Tumor DNA
24%
Immune Checkpoints
19%
Blood Plasma
17%
Droplet Digital Polymerase Chain Reaction
15%
Human Leukocyte Antigen
12%
Genotyping
9%
Genomics
8%
Epidermal Growth Factor Receptor
8%
Targeted Therapy
7%
PD-L1
7%
Promoter Region
6%
T Cell
6%
Overall Survival
5%
Progression Free Survival
5%
Whole Genome Sequencing
5%
ABCB5
5%
Flow Cytometry
5%
RNA
5%
Cell Death
5%
Gemcitabine
5%
Murine
5%